Biopharmaceutical company CANbridge Life Sciences announced on Monday the appointment of Annie Teng, MD as the new VP of its Clinical Development and Medical Affairs.
In addition, the company has named Janny Wang as the new director of its Quality Assurance.
Most recently, Dr Teng has served as medical director, Specialty Care, as well as head of Biology & Early Development at Sanofi, respectively.
Previously, Dr Teng was employed as disease area head for Oncology and Immunology at Bristol-Meyer-Squibb China, worked in oncology at Pfizer & Pharmacia (later acquired by Pfizer) as well as started her medical career in pediatrics at Chinese PLA Hospital.
Recently, Wang worked for 11 years with Teva Pharmaceutical Industry subsidiary, Teva Pharmaceutical & Chemical, in China, including quality assurance and quality control associate director as well as quality control manager at the Bayer Pharmaceuticals subsidiary, Dihon Pharmaceutical Group, in China.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer